Navigation Links
EasyOne Pro from ndd Medical Technologies Chosen Again as the Exclusive PFT Testing Technology in Phase 2 of COPDGene Study
Date:7/24/2014

ANDOVER, Mass., July 24, 2014 /PRNewswire/ -- ndd Medical Technologies, a leader in innovative mobile pulmonary function testing (PFT) employing precise ultrasound technology, announced that its EasyOne Pro® has been chosen as the instrument to measure Carbon Monoxide Diffusing Capacity (DLCO) for phase 2 of the COPDGene® Study, the most comprehensive study of Chronic Obstructive Pulmonary Disease (COPD) ever undertaken.  COPD is now the third leading cause of death in the U.S. and affects millions of people worldwide. 

In COPDGene phase 1, a multicenter, 10,000-patient study to identify genetic, epidemiological and radiological characteristics of COPD, ndd Medical's market-leading spirometry equipment, EasyOne® Plus, was used for all spirometry testing.  COPDGene phase 2 added the key test, DLCO, to measure aspects of the lung membrane and the ability of the lungs to oxygenate the blood.

"Spirometry, which has classically been used to measure, diagnose and manage COPD, may not be as accurate as previously thought," says Robert Jensen, Ph.D., head of the study's PFT Quality Assurance.   "The EasyOne Pro provides both DLCO and spirometry testing and is the only instrument incorporating molar mass measurement for very precise analysis." 

According to Jensen, investigators raised additional funds to purchase the EasyOne Pro at all 21 study centers.  The decision was made in part because of the "extraordinary stability" of its ultrasound measurement of volumes and flows, but also for its imperviousness to temperature, barometric pressure, altitude and other factors that can result in faulty measurements of DLCO and spirometry.

Among the goals of the COPDGene study, initially funded with a $37 million grant from the National Institutes of Health, is the understanding of genetic information that contributes or is associated with a person's risk for developing COPD, potentially leading to new therapeutic approaches to control the disease and improve quality of life for COPD patients. 

COPD is the umbrella term for a variety of progressive lung diseases— most commonly emphysema and chronic bronchitis— marked by damaged lung tissue, making it difficult to breathe.

About ndd Medical Technologies, Inc.

With 40 percent of the U.S. spirometry market share, ndd Medical Technologies offers innovative, easy-to-use pulmonary function testing instruments that help clinicians diagnose lung disease with greater precision for optimal treatment.  Its EasyOne® and EasyOne Pro® portable instruments take up just 12 inches of space to take lung function testing wherever it is needed, in the pulmonary function laboratory, at the bedside or in the field. ndd's devices measure DLCO, FRC, LCI and FVC with  their patented Ultrasonic TrueFlow™ technology, which requires no calibration, eliminates problems associated with traditional methods of flow measurement, making testing fast, reliable and error free.  To learn more, visit www.nddmed.com.


'/>"/>
SOURCE ndd Medical, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. Medical Device Developers - Network at BIOMEDevice Boston Next Week
3. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
4. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
5. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
6. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Essential Medical Dismisses Patent Case against Masimo and Cercacor
9. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
10. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
11. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... and Company (NYSE: LLY ) today announced that the ... patent would not presently be infringed by Actavis marketing pemetrexed ... Italy and Spain ... --> --> In ... Lilly,s patent would be indirectly infringed by Actavis marketing certain ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
(Date:2/11/2016)... 11, 2016 The primary goal of this ... patterns on the usage of liquid biopsy. Key information ... - Timeframe of liquid biopsy adoption amidst future ... Evs—by organization type - Sample inflow to conduct liquid ... stool, serum, and so on. - Correlation analysis of ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Basketball is a game for everyone, not ... Peety PoppersTM series, sign language translation is featured in the top right of the ... Peety PoppersTM lessons has a sign language translator to teach kids the game and ...
(Date:2/11/2016)... ... February 12, 2016 , ... Fitbody Personal Training offers outdoor training ... exciting way to get fit and healthy. Located in Phoenixville, PA, the classes are ... class designed for horseback riders who want to lose weight and tone up. This ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... participated in the American Osteopathic Association’s (AOA) Match Program Tuesday, February 9, taking ... Program places students into osteopathic graduate medical education positions across the country. Of ...
(Date:2/11/2016)... ... February 12, 2016 , ... The Journal of ... from 0.416 in 2013. The SJR uses data taken from the Scopus database (Elsevier ... the number of citations received by the journal over a three year period and ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... diabetes has been gearing up for their simultaneous grand openings in March. All ... right now that you’re probably wondering, is reversing diabetes possible? According to this ...
Breaking Medicine News(10 mins):